- ISIN
- US05280R1005
- CUSIP
- 05280R100
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jun 22, 2018
Highlights
- Market Cap
- $396.55M
- Enterprise Value
- $348.65M
- EPS (TTM)
- -$1.09
- Total Revenue (TTM)
- $92.59M
- Gross Profit (TTM)
- -$10.36M
- EBITDA (TTM)
- -$253.48M
- Year Range
- $1.18 - $2.70
- Target Price
- $8.87
- ROA (TTM)
- -54.80%
- ROE (TTM)
- -265.41%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
AUTL Performance Chart
Autolus Therapeutics plc (AUTL) is down 25.1% since the beginning of the year. At $1 per share, AUTL is trading 44.8% below its 52-week high of $3. Investors who bought $1,000 worth of AUTL shares 5 years ago would now be looking at an investment worth $218.
Loading charts...
Returns By Period
Autolus Therapeutics plc (AUTL) has returned -25.13% so far this year and -27.32% over the past 12 months.
Autolus Therapeutics plc
- 1D
- -1.32%
- 1M
- -12.35%
- YTD
- -25.13%
- 6M
- -13.87%
- 1Y
- -27.32%
- 3Y*
- -16.40%
- 5Y*
- -26.25%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
AUTL Monthly Returns History
Based on dividend-adjusted daily data since Jun 22, 2018, AUTL's average daily return is -0.02%, while the average monthly return is -0.55%.
Historically, 38% of months were positive and 62% were negative. The best month was May 2023 with a return of +71.8%, while the worst month was Apr 2024 at -42.3%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 9 months.
On a daily basis, AUTL closed higher 47% of trading days. The best single day was May 12, 2021 with a return of +35.5%, while the worst single day was Dec 9, 2022 at -38.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -31.16% | 24.82% | -19.30% | 2.17% | 32.62% | -20.32% | -25.13% | ||||||
| 2025 | -5.96% | -21.72% | -10.40% | -9.03% | 24.11% | 30.29% | 5.26% | -37.50% | 8.67% | -4.91% | -9.03% | 41.13% | -15.32% |
| 2024 | -6.52% | -0.33% | 6.33% | -42.32% | 13.86% | -16.95% | 34.77% | -16.20% | -7.63% | -7.16% | -1.48% | -29.22% | -63.51% |
| 2023 | 13.16% | -9.77% | -5.15% | -1.63% | 71.82% | -23.47% | 35.71% | -0.62% | -27.41% | 21.03% | 51.77% | 50.47% | 238.95% |
| 2022 | -23.12% | -6.27% | 11.50% | -25.18% | -12.18% | 3.28% | -1.41% | 18.28% | -35.15% | 33.18% | -7.37% | -28.03% | -63.39% |
| 2021 | -17.79% | -12.38% | -11.02% | 1.57% | 13.92% | 0.15% | -19.88% | 29.14% | -4.66% | -14.81% | 15.23% | -19.28% | -41.95% |
Benchmark Metrics
Autolus Therapeutics plc has an annualized alpha of -17.81%, beta of 1.06, and R2 of 0.07 versus S&P 500 Index. Calculated based on daily prices since June 22, 2018.
- This stock participated in 204.95% of S&P 500 Index downside but only 73.71% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.07 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -17.81%
- Beta
- 1.06
- R²
- 0.07
- Upside Capture
- 73.71%
- Downside Capture
- 204.95%
Return for Risk
Risk / Return Rank
AUTL ranks 28 for risk / return — below 28% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Autolus Therapeutics plc (AUTL) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| AUTL | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.39 | ||
| Sortino ratioReturn per unit of downside risk | -2.83 | ||
| Omega ratioGain probability vs. loss probability | 0.99 | 1.37 | -0.38 |
| Calmar ratioReturn relative to maximum drawdown | -0.50 | 2.78 | -3.28 |
| Martin ratioReturn relative to average drawdown | -0.69 | 12.44 | -13.13 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Autolus Therapeutics plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Autolus Therapeutics plc was 97.63%, occurring on Apr 10, 2025. The portfolio has not yet recovered.
The current Autolus Therapeutics plc drawdown is 96.90%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -97.63%Apr 2025 | 6y 5mo | — | 7y 7moNov 2018 - now |
Rate-hike selloffLate 2018 | -27.36%Oct 2018 | 1mo | 28d | 1mo 28dSep 2018 - Nov 2018 |
2018 bear market2018 | -25.50%Jul 2018 | 21d | 1mo 3d | 1mo 24dJun 2018 - Aug 2018 |
2018 pullback2018 | -5.65%Aug 2018 | 3d | 15d | 18dAug 2018 - Sep 2018 |
Drawdown Indicators
| AUTL | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.63% | -56.78% | -40.85% |
Max Drawdown (1Y)Largest decline over 1 year | -54.85% | -9.10% | -45.75% |
Max Drawdown (3Y)Largest decline over 3 years | -84.36% | -18.90% | -65.46% |
Max Drawdown (5Y)Largest decline over 5 years | -84.53% | -25.43% | -59.10% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -96.90% | -1.80% | -95.10% |
Average DrawdownAverage peak-to-trough decline | -81.33% | -10.71% | -70.62% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 39.84% | 2.03% | +37.81% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Autolus Therapeutics plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Autolus Therapeutics plc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for AUTL relative to other companies in the Biotechnology industry. Currently, AUTL has a P/S ratio of 4.3. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for AUTL in comparison with other companies in the Biotechnology industry. Currently, AUTL has a P/B value of 3.6. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with AUTL
Add Autolus Therapeutics plc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with AUTL